Literature DB >> 12572660

An evaluation of population D-optimal designs via pharmacokinetic simulations.

Andrew C Hooker1, Marco Foracchia, Michael G Dodds, Paolo Vicini.   

Abstract

One goal of large scale clinical trials is to determine how a drug is processed by, and cleared from, the human body [i.e., its pharmacokinetic (PK) properties] and how these PK properties differ between individuals in a population (i.e., its population PK properties). Due to the high cost of these studies and the limited amount of data (e.g., blood samples) available from each study subject, it would be useful to know how many measurements are needed and when those measurements should be taken to accurately quantify population PK model parameters means and variances. Previous studies have looked at optimal design strategies of population PK experiments by developing an optimal design for an individual study (i.e., no interindividual variability was considered in the design), and then applying that design to each individual in a population study (where interindividual variability is present). A more algorithmically and informationally intensive approach is to develop a population optimal design, which inherently includes the assessment of interindividual variability. We present a simulation-based evaluation of these two design methods based on nonlinear Gaussian population PK models. Specifically, we compute standard individual and population D-optimal designs and compare population PK model parameter estimates based on simulated optimal design measurements. Our results show that population and standard D-optimal designs are not significantly different when both designs have the same number of samples per individual. However, population optimal designs allow for sampling schedules where the number of samples per individual is less than the number of model parameters, the theoretical limit allowed in standard optimal design. These designs with a low number of samples per individual are shown to be nearly as robust in parameter estimation as standard D-optimal designs. In the limit of just one sample per individual, however, population D-optimal designs are shown to be inadequate.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12572660     DOI: 10.1114/1.1533074

Source DB:  PubMed          Journal:  Ann Biomed Eng        ISSN: 0090-6964            Impact factor:   3.934


  11 in total

1.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

2.  Robust population pharmacokinetic experiment design.

Authors:  Michael G Dodds; Andrew C Hooker; Paolo Vicini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-02       Impact factor: 2.745

Review 3.  A pragmatic approach to the design of population pharmacokinetic studies.

Authors:  Amit Roy; Ene I Ette
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

4.  Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.

Authors:  Andrew Hooker; Paolo Vicini
Journal:  AAPS J       Date:  2005-11-01       Impact factor: 4.009

5.  A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.

Authors:  Federico Galvanin; Carlo C Ballan; Massimiliano Barolo; Fabrizio Bezzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-04       Impact factor: 2.745

6.  A model-based meta-analysis of monoclonal antibody pharmacokinetics to guide optimal first-in-human study design.

Authors:  Jasmine P Davda; Michael G Dodds; Megan A Gibbs; Wendy Wisdom; John Gibbs
Journal:  MAbs       Date:  2014-05-16       Impact factor: 5.857

7.  Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.

Authors:  Monica Gandhi; Leslie Z Benet; Peter Bacchetti; Ann Kalinowski; Kathryn Anastos; Alan R Wolfe; Mary Young; Mardge Cohen; Howard Minkoff; Stephen J Gange; Ruth M Greenblatt
Journal:  J Acquir Immune Defic Syndr       Date:  2009-04-15       Impact factor: 3.731

8.  Using Animal Instincts to Design Efficient Biomedical Studies via Particle Swarm Optimization.

Authors:  Jiaheng Qiu; Ray-Bing Chen; Weichung Wang; Weng Kee Wong
Journal:  Swarm Evol Comput       Date:  2014-10-01       Impact factor: 7.177

9.  Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain.

Authors:  A Taneja; J Nyberg; E C M de Lange; M Danhof; O Della Pasqua
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-30       Impact factor: 2.745

10.  The effect of using a robust optimality criterion in model based adaptive optimization.

Authors:  Eric A Strömberg; Andrew C Hooker
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-06       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.